Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 892 participants.
Also called NCT07040085
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 892 participants
- Registry
-
NCT07040085
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07040085. Randomized; double masking; primary purpose treatment. Start 2025-08-05 (anticipated); primary completion 2027-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke
- Condition
- Stroke
- Intervention (Drug)
- Y-6
- Intervention (Drug)
- Y-6 placebo
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- Neurodawn Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07040085- Content hash
b40810a1121f2cd7603e66a323e639398bcbc1d9d108f88a00f6764ebc0a739e